Overview

This trial is active, not recruiting.

Condition corneal epithelial defect
Treatments conventional therapy plus umbilical cord serum eye drop, conventional therapy
Phase phase 1
Sponsor Shahid Beheshti Medical University
Collaborator Ophthalmic Research Center
Trial identifier NCT01168375, 8742

Summary

80 diabetic patients underwent vitrectomy and had no history of Eye herpes infection, Refractive surgery, Autoimmune disease, Immune deficiency will be randomized into two groups (double blind)to evaluate the role of umbilical cord serum therapy on improvement of corneal epithelial defect following diabetic vitrectomy. Both groups will take the conventional medication including Chloramphenicol, Betamethasone, Cycloplegic eye drops besides the case group will take umbilical cord serum eye drop in the eye operated. After surgery the corneal epithelial defect will be measured by slit lamp.

United States No locations recruiting
Other Countries No locations recruiting

Primary Outcomes

Measure
measurement of corneal epithelial defect
time frame:

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Diabetic patients with corneal epithelial defect following diabetic vitrectomy at labbafinejad Hospital Exclusion Criteria: - Any history of Eye herpes infection, Refractive surgery, Autoimmune disease, Immune deficiency - Patients with one eye - Use of any eye drops except Chloramphenicol, Betamethasone, Cycloplegic and contact lens for corneal epithelial defect

Additional Information

Official title The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy
Trial information was received from ClinicalTrials.gov and was last updated in July 2010.
Information provided to ClinicalTrials.gov by Shahid Beheshti Medical University.